Effects of gadolinium‐based MRI contrast agents on liver tissue

Mercantepe, Tolga; Tümkaya, Levent; Çeliker, Fatma Beyazal; Suzan, Zehra Topal; Çınar, Seda; Akyıldız, Kerimali; Mercantepe, Filiz; Yılmaz, Adnan

doi:10.1002/jmri.26031

Cited by 18 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 29 ] Mercantepe and coworkers reported in their study that linear or macrocyclic GBCAs had similar toxicity effects on liver tissue as a result of administration. [ 9 ] In this study, we observed that the effects of linear or macrocyclic GBCAs on lung tissue were similar.…”

Section: Discussionsupporting

confidence: 53%

Effects of gadodiamide and gadoteric acid on lung tissue: A comparative study

Çeliker

Tümkaya

Suzan

et al. 2022

J Biochem & Molecular Tox

Self Cite

View full text Add to dashboard Cite

We set out to investigate the effects of gadodiamide and gadoteric acid, used for magnetic resonance imaging, on the lungs. In this study, 32 male Sprague Dawley rats were used. These were allocated into four groups; The first group (control) was untreated. The second group received isotonic saline on the first and fourth days of the week for 5 weeks. Following the same schedule, the third and fourth groups received a total of 2 mg/kg gadodiamide and gadoteric acid, respectively, in place of saline. The alveolar Wall thickness was evaluated. Gadodiamide and gadoteric acid significantly increased the numbers of collagen-3 and caspase-3 positive cells in the lung tissue (p < 0.05). In addition, these two substances increased the alveolar Wall thickness (p < 0.05). Furthermore, they increased the levels of malondialdehyde and glutathione (p < 0.05). This study demonstrates that both linear and macrocyclic contrast agents are toxic for the lungs in rats.

show abstract

Section: Discussionsupporting

confidence: 53%

Effects of gadodiamide and gadoteric acid on lung tissue: A comparative study

Çeliker

Tümkaya

Suzan

et al. 2022

J Biochem & Molecular Tox

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most frequent side effects were found as anaphylactoid/hypersensitivity reactions, headache, nausea, dizziness, injection site reactions, feeling www.nature.com/scientificreports www.nature.com/scientificreports/ hot, vomiting and dysgeusia 24 . In an animal model, Gd-based contrast agents were shown to induce necrosis and apoptosis in liver 25 .…”

Section: Discussionmentioning

confidence: 99%

Gadolinium labelled nanoliposomes as the platform for MRI theranostics: in vitro safety study in liver cells and macrophages

Šimečková

Hubatka

Kotouček

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Gadolinium (Gd)-based contrast agents are extensively used for magnetic resonance imaging (MRi). Liposomes are potential nanocarrier-based biocompatible platforms for development of new generations of MRi diagnostics. Liposomes with Gd-complexes (Gd-lip) co-encapsulated with thrombolytic agents can serve both for imaging and treatment of various pathological states including stroke. in this study, we evaluated nanosafety of Gd-lip containing pe-DtpA chelating Gd +3 prepared by lipid film hydration method. We detected no cytotoxicity of Gd-lip in human liver cells including cancer HepG2, progenitor (non-differentiated) HepaRG, and differentiated HepaRG cells. Furthermore, no potential side effects of Gd-lip were found using a complex system including general biomarkers of toxicity, such as induction of early response genes, oxidative, heat shock and endoplasmic reticulum stress, DnA damage responses, induction of xenobiotic metabolizing enzymes, and changes in sphingolipid metabolism in differentiated HepaRG. Moreover, Gd-lip did not show pro-inflammatory effects, as assessed in an assay based on activation of inflammasome NLRP3 in a model of human macrophages, and release of eicosanoids from HepaRG cells. in conclusion, this in vitro study indicates potential in vivo safety of Gd-lip with respect to hepatotoxicity and immunopathology caused by inflammation.Gadolinium (Gd) -based contrast agents are extensively used for magnetic resonance imaging (MRI). Gd +3 forms insoluble phosphate salt in biological fluids and cultivation media. Therefore, Gd +3 is used in complexed forms of soluble chelates. These complexes are believed to be stable and non-toxic because of a high stability constant 1 . Recently, accumulation of Gd-based contrast agents has been demonstrated in various organs like kidney, liver and nervous system. It is supposed that toxic effects can be caused by dissociation of Gd ions from chelated complexes 2,3 . Case reports pointed to the induction of nephrotoxicity, hepatotoxicity and neurotoxicity and rare acute adverse reactions to Gd-based contrast agents were also observed in patients 4 .Liposomes, phospholipid-based vesicles, are widely studied as potential nanocarriers of both MRI contrast agents, including Gd +3 , and drug molecules, such as thrombolytic agents 1,5 . Therefore, liposomes can serve as diagnostic as well as theranostic agents for imaging and treatment of various pathological states and illnesses such as cancer, ischemic stroke and vasculature of different organs including liver and spleen 6,7 . Thus, liposomes represent a favourable platform for a new generation of targeted diagnostic and theranostic systems 8 .Liposomes composed of a Gd-chelating lipid, such as 1,2-distearoyl-sn-glycero-3-p hosphoethanolamine-N-diethylenetriaminepentaacetic acid (PE-DTPA (Gd)), can be easily modified to capture targeting moieties on their surface using different chemistries including copper-free click-chemistry. Moreover, different surface coating of liposomes including polyethylene glycol, hyalu...

show abstract

“…[29,59,[61][62][63] While the mechanism has not been unequivocally proven, the presence of Gadolinium deposits suggests that the GCCA release toxic, free Gadolinium most likely from acidic lysosomal compartments within the Kupffer cells. [111][112][113] While nanocrystals are also taken up by Kupffer cells in the liver, the remarkable chemical stability of these materials, even under mildly acidic conditions, should limit the release of free Gadolinium and reduce the likelihood of this particular toxicity mechanism (Figures S9 and S10, Supporting Information).…”

Section: Detecting Nonalcoholic Fatty Liver Disease With Gadolinium Oxide Nanoplatesmentioning

confidence: 99%

2D Gadolinium Oxide Nanoplates as T₁ Magnetic Resonance Imaging Contrast Agents

Stinnett

Taheri

Villanova

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

Millions of people a year receive magnetic resonance imaging (MRI) contrast agents for the diagnosis of conditions as diverse as fatty liver disease and cancer. Gadolinium chelates, which provide preferred T1 contrast, are the current standard but face an uncertain future due to increasing concerns about their nephrogenic toxicity as well as poor performance in high‐field MRI scanners. Gadolinium‐containing nanocrystals are interesting alternatives as they bypass the kidneys and can offer the possibility of both intracellular accumulation and active targeting. Nanocrystal contrast performance is notably limited, however, as their organic coatings block water from close interactions with surface Gadoliniums. Here, these steric barriers to water exchange are minimized through shape engineering of plate‐like nanocrystals that possess accessible Gadoliniums at their edges. Sulfonated surface polymers promote second‐sphere relaxation processes that contribute remarkable contrast even at the highest fields (r1 = 32.6 × 10−3 m Gd−1 s−1 at 9.4 T). These noncytotoxic materials release no detectable free Gadolinium even under mild acidic conditions. They preferentially accumulate in the liver of mice with a circulation half‐life 50% longer than commercial agents. These features allow these T1 MRI contrast agents to be applied for the first time to the ex vivo detection of nonalcoholic fatty liver disease in mice.

show abstract

Effects of gadolinium‐based MRI contrast agents on liver tissue

Abstract: 1 Technical Efficacy: Stage 4 J. Magn. Reson. Imaging 2018;47:1367-1374.

Cited by 18 publications

References 40 publications

Effects of gadodiamide and gadoteric acid on lung tissue: A comparative study

Effects of gadodiamide and gadoteric acid on lung tissue: A comparative study

Gadolinium labelled nanoliposomes as the platform for MRI theranostics: in vitro safety study in liver cells and macrophages

2D Gadolinium Oxide Nanoplates as T₁ Magnetic Resonance Imaging Contrast Agents

Contact Info

Product

Resources

About

Effects of gadolinium‐based MRI contrast agents on liver tissue

Abstract: 1 Technical Efficacy: Stage 4 J. Magn. Reson. Imaging 2018;47:1367-1374.

Cited by 18 publications

References 40 publications

Effects of gadodiamide and gadoteric acid on lung tissue: A comparative study

Effects of gadodiamide and gadoteric acid on lung tissue: A comparative study

Gadolinium labelled nanoliposomes as the platform for MRI theranostics: in vitro safety study in liver cells and macrophages

2D Gadolinium Oxide Nanoplates as T1 Magnetic Resonance Imaging Contrast Agents

Contact Info

Product

Resources

About

2D Gadolinium Oxide Nanoplates as T₁ Magnetic Resonance Imaging Contrast Agents